Lovato Kaitlyn, Loskot Danielle, Gelin Christine, Zhu Lu, Chaudhry Charu, Vellore Nadeem A, Del Rosario Amanda, Courtney Taylor, Miller Seth, Cho Ji-Hoon, Bell-Temin Harris, Venable Jennifer D, Brazeau Jean-François
Discovery Chemistry, Therapeutics Discovery, Johnson & Johnson, 3210 Merryfield RowLa Jolla, San Diego, California 92121, United States.
Discovery Technology and Molecular Pharmacology, Therapeutics Discovery, Johnson & Johnson, Spring House, Philadelphia, Pennsylvania 19477, United States.
J Med Chem. 2025 May 22;68(10):10061-10074. doi: 10.1021/acs.jmedchem.4c03157. Epub 2025 May 8.
Heterobifunctional degraders (also known as proteolysis-targeting chimeras or PROTACs) have emerged in drug discovery as an alternative therapeutic modality for targeting disease-causing proteins that are challenging to modulate with standard protein inhibitors. Almost all current PROTACs under clinical studies use the E3 ligase cereblon (CRBN) to hijack the ubiquitin-proteasome system. In this study, we used high-throughput experimentation to identify new conditions to access carbon-carbon bonds on our CRBN warheads. These efforts led to the discovery that alkyl-connected CRBN binders demonstrate improved cell permeability and reduced neosubstrate activity when compared with their amide counterparts. To further demonstrate the value of this protocol and the resulting alkyl connection point, these conditions were utilized as a final synthetic step to produce a heterobifunctional BRD4 degrader with an improved CRBN neosubstrate selectivity profile compared to its amide counterpart.
异双功能降解剂(也称为蛋白酶靶向嵌合体或PROTACs)已在药物研发中崭露头角,成为一种针对致病蛋白的替代治疗方式,而这些致病蛋白用标准蛋白抑制剂进行调节具有挑战性。几乎所有正在进行临床研究的当前PROTACs都使用E3连接酶cereblon(CRBN)来劫持泛素-蛋白酶体系统。在本研究中,我们利用高通量实验来确定在我们的CRBN弹头上去构建碳-碳键的新条件。这些努力导致发现,与酰胺连接的CRBN结合剂相比,烷基连接的CRBN结合剂表现出改善的细胞通透性和降低的新底物活性。为了进一步证明该方案和所得烷基连接点的价值,这些条件被用作最终合成步骤,以生产一种异双功能BRD4降解剂,与酰胺连接的对应物相比,其具有改善的CRBN新底物选择性谱。